New Blood Test Makes Colorectal Cancer Screening Easier

Getting screened for colorectal cancer just became as simple as a routine blood draw, thanks to a breakthrough FDA approval that could save thousands of lives.

The Shield blood test is now the first and only FDA-approved blood screening for colorectal cancer, offering a new option for people over 45 at average risk. Unlike traditional colonoscopies, this test can be done during a regular doctor visit with a simple blood draw.

The timing couldn't be more critical. This year alone, 6,520 Pennsylvanians will be diagnosed with colorectal cancer, and more than 2,200 will die from the disease. Many of these deaths could be prevented with early detection.

Sherri Chippo, a Marine veteran and cancer survivor from Hampden Township, Pennsylvania, knows firsthand how crucial early screening is. As the daughter of parents who lost their battle with cancer, she's making it her mission to spread awareness about this new testing option.

The statistics are striking. You're up to seven times more likely to survive colorectal cancer when it's caught early. Yet many people avoid screening because they find colonoscopies too invasive or uncomfortable.

That's where the Shield test changes everything. It works just like any other blood test your primary care doctor might order during an annual checkup. No special preparation, no invasive procedures, just a simple blood draw.

The accessibility extends beyond convenience. The test is covered by Medicare, VA Community Care, and TRICARE, meaning Pennsylvania's aging communities, veterans, and active duty and reserve members at average risk can get screened with little to no cost.

The Ripple Effect

When screening becomes easier, more people get tested. When more people get tested, more cancers get caught early. And when cancers get caught early, survival rates jump dramatically.

This simple blood test could remove one of the biggest barriers to colorectal cancer screening. For people who have put off colonoscopies for years due to discomfort or anxiety, Shield offers a fresh start and a second chance at early detection.

The implications reach far beyond Pennsylvania. As word spreads about this accessible screening option, communities nationwide could see more people taking that crucial first step toward prevention.

Colorectal cancer is one of the most treatable cancers when detected early, yet it remains the second leading cause of cancer deaths in the United States. This new blood test gives everyone a fighting chance to catch it in time.